<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene H69del;V70del;Y144del;E484K;N501Y;A570D;P681H;T716I;S982A;D1118H literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.H69_V70del;Y144del;E484K;N501Y;A570D;P681H;T716I;S982A;D1118H</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Neutralization capacity GMT of 27 subjects' sera post-infection was markedly worse against B.1.1.7 + E484K than the lineage alone, with a 11.4x drop.<br/> (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K  variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed.<br/> (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Neutralization efficiency (ID50) against B.1.1.7+E484K reduced 2.8x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/>Compare with 1.2x reduction for B.1.1.7 without E484K. (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
